Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 446 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Blood and tissue samples Clear all
Active, not recruiting No phase listed Observational

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

NCT05415358
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell
Interventions
Blood and tissue samples
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Terminated Not applicable Interventional

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

NCT05911243
View directory record Official record
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Acupressure Therapy, Best Practice, Biospecimen Collection, Questionnaire Administration
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Recruiting No phase listed Observational

Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer

NCT04742608
View directory record Official record
Conditions
Thyroid Gland Carcinoma, Thyroid Gland Nodule
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

NCT00876915
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
dalteparin injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Sacramento, California • Buffalo, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Sep 10, 2026, 10:55 AM EDT
Terminated Phase 1 Interventional

RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer

NCT01192763
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis, pharmacological study, neoadjuvant therapy, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
6
States / cities
Beverly Hills, California • Duarte, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Sep 10, 2026, 10:55 AM EDT
Recruiting Phase 2 Interventional

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

NCT06311214
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Enfortumab Vedotin, Immunohistochemistry Staining Method, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sacituzumab Govitecan, Trastuzumab Deruxtecan
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
27
States / cities
Duarte, California • Encinitas, California • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer

NCT00699907
View directory record Official record
Conditions
Ovarian Cancer
Interventions
flutamide
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 83 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 10, 2026, 10:55 AM EDT
Recruiting No phase listed Observational

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

NCT06401421
View directory record Official record
Conditions
Breast Cancer
Interventions
ctDNA MRD test
Diagnostic Test
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
53
States / cities
Anchorage, Alaska • Palo Alto, California • Torrance, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Recruiting No phase listed Observational

Social Determinants of Health in Hepatobiliary Cancer Patients

NCT06053333
View directory record Official record
Conditions
Malignant Hepatobiliary Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Active, not recruiting No phase listed Observational

Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer

NCT04856046
View directory record Official record
Conditions
Resectable Hepatocellular Carcinoma
Interventions
Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Terminated Not applicable Interventional

EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer

NCT00896961
View directory record Official record
Conditions
Stage I Adult Soft Tissue Sarcoma, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Adult Soft Tissue Sarcoma, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Adult Soft Tissue Sarcoma, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
Interventions
EF5, diagnostic laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 10, 2026, 10:55 AM EDT
Completed No phase listed Observational

Developing Mouse Models of Breast Cancer Using Tissue Samples From Women With Breast Cancer

NCT00897468
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis, medical chart review
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Sep 10, 2026, 10:55 AM EDT
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
336
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 259 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Terminated Phase 2 Interventional Results available

RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy

NCT01193868
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 10, 2026, 10:55 AM EDT
Active, not recruiting Early Phase 1 Interventional

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

NCT04494113
View directory record Official record
Conditions
Endometrial Serous Adenocarcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Resection, Triapine
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Coral Gables, Florida • Deerfield Beach, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Active, not recruiting No phase listed Observational

Biological Sample Repository for Gastrointestinal Disorders

NCT05874726
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Obesity, Primary, Gastro-Intestinal Disorder, Overweight and Obesity, Overweight, Overweight or Obesity, Diabetes Type 2, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemias, Sleep Apnea, GERD, Gastroesophageal Reflux, Musculoskeletal Pain Disorder, Cancer
Interventions
Blood Collection, Urine Collection, Tissue Sample Collection
Diagnostic Test
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 10, 2026, 10:55 AM EDT
Recruiting No phase listed Observational

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

NCT05672615
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer
Interventions
Questionnaires, Daily Mood Diaries, Urine Specimen Collection, Research Blood Draw, Utilize excess tissue from a standard of care procedure
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

NCT00720304
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization, polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, therapeutic conventional surgery, intensity-modulated radiation therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 10, 2026, 10:55 AM EDT
Terminated Not applicable Interventional Results available

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT02132884
View directory record Official record
Conditions
Malignant Pericardial Effusion, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cytology specimen collection procedure, therapeutic procedure, targeted therapy, laboratory biomarker analysis
Other · Procedure · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 10, 2026, 10:55 AM EDT
Recruiting Not applicable Interventional

Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury

NCT02577731
View directory record Official record
Conditions
Trauma Injury
Interventions
Bone marrow collection, Blood collection, Clinical data collection
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 10, 2026, 10:55 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis

NCT05862805
View directory record Official record
Conditions
Menstrual Bleeding, Heavy
Interventions
Sample Collection and Endometrial Biopsy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 10, 2026, 10:55 AM EDT
Completed No phase listed Observational

Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy

NCT06089967
View directory record Official record
Conditions
Cancer, Immune-related Adverse Event
Interventions
Medical chart review
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 10, 2026, 10:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Modulating Glucose Tolerance With Dietary Tyrosine

NCT03872557
View directory record Official record
Conditions
Glucose Tolerance
Interventions
Tyrosine (TYR) Supplementation
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 10, 2026, 10:55 AM EDT
Terminated Not applicable Interventional Results available

Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid

NCT01409811
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
Interventions
zoledronic acid, laboratory biomarker analysis, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 10, 2026, 10:55 AM EDT